Anuradha Alahari

Associate Editor / Section Editor

Medical writer with more than 10 years of experience in scientific and regulatory writing. Previous extensive experience in academic research in India, US, and France. Currently, Senior Medical Writer at Parexel International (https://www.parexel.com), located in France.

LinkedIn: www.linkedin.com/in/anuradhaalahari

Google Scholar: https://scholar.google.com/citations?user=efRprygAAAAJ&hl=en&oi=ao

                                                     anuradha.alahari@parexel.com 

Contributions

News from the EMA - Volume 33, Issue 3

The articles included in this section are a selection from the European Medicines Agency’s News and Press Releases archive. Medical Writing. 2024;33(3):72–78.

News from the EMA - Volume 33, Issue 2

Section Editor: Anuradha Alahari The articles included in this section are a selection from the European Medicines Agency’s News and Press Releases archive. More information can be found on the Agency’s website: www.ema.europa.eu. Medical…

Managing protocol development with international teams: Soft skill perspectives from a global team of protocol writers - Volume 33, Issue 2

Clinical trial protocol development forms part of the critical path for launching a trial, which means timelines are tight and progress must be fast and sustained throughout the protocol’s development. In order to be successful, medical writers…

News from the EMA - Volume 33, Issue 1

The articles included in this section are a selection from the European Medicines Agency’s News and Press Releases archive. More information can be found on the Agency’s website: www.ema.europa.eu. Section Editor: Anuradha Alahari Medical…

News from the EMA - Volume 32, Issue 4

Section Editor: Anuradha Alahari Medical Writing. 2023;32(4):64–68. https://doi.org/10.56012/oknc4756

News from the EMA - Volume 32, Issue 3

Anuradha Alahari (section editor)   EMA recommends revocation of authorisation for sickle cell disease medicine Adakveo OPEN framework extended to a wider range of medicines Global regulators agree on way forward to adapt COVID-19 vaccines to…

News from the EMA - Volume 32, Issue 2

This section offers a selection from recent news items from the EMA. Medical Writing. 2023;32(2)86–91.

News from the EMA - Volume 32, Issue 1

This roundup of news from the EMA includes information on vaccines to protect against dengue, therapy to treat transplant patients with post-transplant lymphoproliferative disease, the withdrawal of marketing authorisations for amfepramone…

News from the EMA - Volume 31, Issue 4

Medical Writing. 2022;31(4)65-69. Section editor: Anuradha Alahari

News from the EMA - Volume 31, Issue 3

News from the EMA - Volume 31, Issue 2

The articles included in this section are a selection from the European Medicines Agency (EMA)’s News and Press Releases archive. More information can be found on the Agency’s website: www.ema.europa.eu. Anuradha Alahari (editor)

News from the EMA - Volume 31, Issue 1

EMA is putting in place special support to developers to replace, reduce and refine animal use for the development, manufacturing and testing of human and veterinary medicines. The Agency is promoting these three principles replace, reduce and…

News from the EMA - Volume 30, Issue 4

Zynteglo is a one-time treatment for a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions. It is a gene therapy that uses a viral vector (or modified virus) to deliver a working gene into…

News from the EMA - Volume 30, Issue 3

Medical writers at EMA have published an “EMA medical terms simplifier” (https://www.ema.europa.eu/en/documents/ot her/ema-medical-terms-simplifier_ en.pdf) on the “Glossaries” page of EMA’s website (under “About us”) to provide public-friendly…

News from the EMA - Volume 30, Issue 2

February 26, 2021 – EMA has recommended granting a marketing authorisation in the European Union (EU) for the first treatment that can be given orally to patients with certain types of spinal muscular atrophy (SMA), a rare and often fatal genetic…

News from the EMA - Volume 29, Issue 4

September 14, 2020 – The Big Data Steering Group set up by EMA and the Heads of Medicines Agencies (HMA) has published its workplan which sets actions to be delivered in 2020–2021. With the European Medicines Regulatory Network focused on the…

News from the EMA - Volume 29, Issue 3

The articles included in this section are a selection from the European Medicines Agency (EMA)’s News and Press Releases archive. More information can be found on the Agency’s website: www.ema.europa.eu.

News from the EMA - Volume 29, Issue 2

The articles included in this section are a selection from the European Medicines Agency (EMA)’s News and Press Releases archive. More information can be found on the Agency’s website: www.ema.europa.eu

News from the EMA - Volume 29, Issue 1

The articles included in this section are an edited selection from the European Medicines Agency (EMA)’s News and Press Releases archive from October 2019 to December 2019. More information can be found on the Agency’s website: www.ema.europa.eu

News from the EMA - Volume 28, Issue 4

The articles included in this section are a selection from the European Medicines Agency (EMA)’s News and Press Releases archive from July 2019 to September 2019. More information can be found on the Agency’s website: www.ema.europa.eu.

News from the EMA - Volume 28, Issue 3

The articles included in this section are a selection from the European Medicines Agency (EMA)’s News and Press Releases archive from April 2019 to June 2019. More information can be found on the Agency’s website: www.ema.europa.eu

News from the EMA - Volume 28, Issue 2

The articles included in this section are a selection from the European Medicines Agency (EMA)’s News and Press Releases archive from January 2019 to March 2019. More information can be found on the Agency’s website: www.ema.europa.eu

News from the EMA - Volume 28, Issue 1

October 5, 2018 and November 16, 2018 – Fluoroquinolones and quinolones are a class of broad-spectrum antibiotics that are active against bacteria of both Gram-negative and Grampositive classes. EMA’s Pharmacovigilance Risk Assessment Committee…

News from the EMA - Volume 27, Issue 4

The articles included in this section are a selection from the European Medicines Agency’s News and Press Release archive from July 2018 to September 2018. More information can be found on the agency’s website: www.ema.europa.eu

News from the EMA - Volume 27, Issue 3

April 12, 2018 – The European Medicines Agency's (EMA) and its European and international partners have successfully strengthened their interactions to improve the oversight of active pharmaceutical ingredient (API) manufacturers worldwide, as…

News from the EMA - Volume 27, Issue 2

The articles included in this section are a selection from the European Medicines Agency’s News and Press Release archive from January 2018 to March 2018. More information can be found on the agency’s website: www.ema.europa.eu

News from the EMA - Volume 27, Issue 1

The articles included in this section are a selection from the European Medicines Agency’s News and Press Release archive from October 2017 to December 2017. More information can be found on the Agency’s website: http://www.ema.europa.eu/

News from the EMA - Volume 26, Issue 4

The articles included in this section are a selection from the European Medicines Agency’s News and Press Release archive from July 2017 to September 2017. More information can be found on the Agency’s website: www.ema.europa.eu

News from the EMA - Volume 26, Issue 3

April, 6, 2017 – Following two years of experience with safety monitoring of nationally authorised medicines via the single assessment of periodic safety update reports (PSURs), the EMA has issued additional guidance and recommendations as part of…

News from the EMA - Volume 26, Issue 2

Conditional marketing authorisations give patients access to important new medicines earlier January 23, 2017 – Conditional marketing authorisation (CMA) can speed up access to medicines for patients with unmet medical needs in the European Union…

News from the EMA - Volume 26, Issue 1

November 15, 2016 — The EMA, in cooperation with the European Commission and the Member States of the EU, is proposing changes to its existing guideline on first-in-human clinical trials, to further improve the safety of trial participants. The…

News from the EMA - Volume 25, Issue 4

The articles included in this section are a selection from the European Medicines Agency’s News and Press Release archive for August 2016 – Oct 2016. More information can be found on the Agency’s website: www.ema.europa.eu of medicines to treat…

News from the EMA - Volume 25, Issue 3

The articles included in this section are a selection from the European Medicines Agency’s news and press release archive for April 2016 to July 2016.

News from the EMA - Volume 25, Issue 2

The articles included in this section are a selection from the European Medicines Agency’s news and press release archive for November 2015 to March 2016.